Kintara Therapeutics Inc. - notizie pubblicate 163 - letture 2.064
KINTARA THERAPEUTICS INC.
Certificate of Incorporation/Bylaws Form 8 K
Item 5.03 amendments to articles of incorporation or bylaws; change in fiscal year. kintara therapeutics, inc. (the "company") previously designated (a) 5,000,000 shares ...
KINTARA THERAPEUTICS INC.
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti VISTA Checkpoint Inhibitor Form 425
Tuhura biosciences enters into exclusivity and right of first offer agreement for kineta, inc.'s kva12123 novel anti-vista checkpoint inhibitor kva12123 is a rationally targeted, a ...
KINTARA THERAPEUTICS INC.
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti VISTA Checkpoint Inhibitor Form 8 K
Tuhura biosciences enters into exclusivity and right of first offer agreement for kineta, inc.'s kva12123 novel anti-vista checkpoint inhibitor kva12123 is a rationally targeted, a ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones Form 8 K
Kintara therapeutics and tuhura biosciences provide update on recent corporate and clinical advancements and outline near term milestones san diego, july 1, 2024 /prnewswire/ -- ki ...
KINTARA THERAPEUTICS INC.
Amendment to Registration of Securities issued in Business Combination Transaction Form S 4/A
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer kintara therapeutics inc. published th ...
KINTARA THERAPEUTICS INC.
Submission of Matters to a Vote of Security Holders Form 8 K
Item 5.07 submission of matters to a vote of security holders. on june 20, 2024, kintara therapeutics, inc. (the "company") held its annual meeting of stockholders (the & ...
KINTARA THERAPEUTICS INC.
Failure to Satisfy Listing Rule - Form 425
Item 3.01. notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing. as previously reported, on december 13, 2023, kintara therapeutics, ...
KINTARA THERAPEUTICS INC.
Failure to Satisfy Listing Rule Form 8 K
Item 3.01. notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing. as previously reported, on december 13, 2023, kintara therapeutics, ...
KINTARA THERAPEUTICS INC.
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) - Form 425
Tuhura biosciences and kintara therapeutics announce positive results from phase 1b trial of ifx-2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant advance ...
KINTARA THERAPEUTICS INC.
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) - Form 8-K
Tuhura biosciences and kintara therapeutics announce positive results from phase 1b trial of ifx-2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant advance ...
KINTARA THERAPEUTICS INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer kintara therapeutics inc. published th ...
KINTARA THERAPEUTICS INC.
Proxy Statement - Form DEF 14A
Def 14a united states securities and exchange commission washington, d.c. 20549 ___________________ schedule 14a ___________________ proxy statement pursuant to section 14(a) of th ...
KINTARA THERAPEUTICS INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
10-q united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☑quarterly report pursuant to section 13 or 15(d) of the securities exchange act ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results - Form 8-K
Kintara therapeutics announces fiscal 2024 third quarter financial results san diego, may 14, 2024/prnewswire/ -- kintara therapeutics, inc. (nasdaq: ktra) ("kintara" or ...
KINTARA THERAPEUTICS INC.
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results - Form 425
Kintara therapeutics announces fiscal 2024 third quarter financial results san diego, may 14, 2024/prnewswire/ -- kintara therapeutics, inc. (nasdaq: ktra) ("kintara" or ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti